首页> 外文会议>American College of Veterinary Internal Medicine Forum Conference >Efficacy of Robenacoxib for the Treatment of Chronic Musculoskeletal Disorder-Associated Pain and Inflammation in Cats
【24h】

Efficacy of Robenacoxib for the Treatment of Chronic Musculoskeletal Disorder-Associated Pain and Inflammation in Cats

机译:雄皂诺昔布治疗慢性肌肉骨骼障碍相关疼痛和炎症的疗效

获取原文

摘要

Chronic musculoskeletal disorder (CSMD) affects an estimated 30 million cats in the US, with no medications approved for this indication. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the mainstay of treatment of musculoskeletal pain and inflammation in other species.We hypothesized that the NSAID robenacoxib would increase objectively-measured physical activity and improve owner-assessed mobility, pain, quality of life, temperament and happiness in cats with CMSD.
机译:慢性肌肉骨骼障碍(CSMD)影响美国估计的3000万只猫,没有批准此迹象的药物。非甾体抗炎药(NSAIDs)是在其他物种中治疗肌肉骨骼疼痛和炎症的主干道。我们假设NSAID罗根昔尼昔布尔将增加客观测量的身体活动,并改善所有者评估的流动性,痛苦,生活质量,生活质量,气质CMSD猫的幸福。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号